生命科学资讯
生物技术与制药领域的最新动态
Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic push
Hims reports 2025 earnings, shares details on GLP-1 pill decisions
安斯泰来以2.4亿美元现金收购Vir前列腺癌药物。
Astellas pays $240M cash for Vir's prostate cancer drug
QurAlis公司ALS药物早期显现积极信号，但疑问犹存。
QurAlis' ALS drug sees early positive signal, but questions remain
瑞士火箭公司收购华大基因子公司Complete Genomics，紧随《生物安全法案》之后
Swiss Rockets buys MGI subsidiary Complete Genomics after Biosecure Act
堡垒生物科技将以2.05亿美元出售优先审评券
Fortress to sell priority review voucher for $205M
美国食品药品监督管理局发布期待已久的个体化治疗新途径指南。
FDA unveils long-awaited guidance on new pathway for individualized therapies
旗舰公司Generate瞄准纳斯达克上市，估值目标超20亿美元
Flagship's Generate targets $2B+ valuation with Nasdaq IPO
艾伯维斥资3.8亿美元在芝加哥建设肥胖与神经科学原料药设施。
AbbVie budgets $380M for obesity and neuroscience API facilities in Chicago
前沿与港湾分别与葛兰素史克、Solstice达成许可协议
Frontier, Harbour do licensing deals with GSK, Solstice
联邦实验为数字健康开辟新市场——前提是成功
A federal experiment opens up a new market for digital health — if it works
罗氏将停止针对杜氏肌营养不良症的骨骼健康治疗研究。
Roche to stop work on bone health treatment for Duchenne
罗氏将停止针对杜氏肌营养不良症的骨健康治疗研究——终点新闻
Roche to stop work on bone health treatment for Duchenne - Endpoints News
默克重组；黑石集团将为强生药物试验提供资金。
Merck reorganizes; Blackstone to fund trials for J&J drug
罕见自闭症基因疗法首次进入临床试验阶段
First test of gene therapy for rare form of autism is underway
吉利德将以78亿美元收购细胞疗法合作伙伴Arcellx。
Gilead to acquire cell therapy partner Arcellx for $7.8B
诺和诺德CagriSema在头对头肥胖试验中不敌礼来Zepbound。
Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
MoonLake在FDA提交前充满"信心"，披露中期关节炎试验成功
MoonLake has 'confidence' ahead of FDA submission, discloses mid-stage arthritis win
潜在Eylea竞争对手令人失望；FDA将审查Moderna流感疫苗；又一罕见病疗法遭拒；及其他动态。
Potential Eylea competitor disappoints; FDA to review Moderna’s flu vaccine; Another rare disease rejection; and more